Pharmacotherapies for Retinal Detachment.
暂无分享,去创建一个
[1] John D Lambris,et al. Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury , 2015, Science Translational Medicine.
[2] H. Ahmadieh,et al. Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial , 2015, Acta ophthalmologica.
[3] Christopher J Brady,et al. CLINICAL MANAGEMENT OF PROLIFERATIVE VITREORETINOPATHY: An Update , 2015, Retina.
[4] S. Grisanti,et al. A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. , 2014, Experimental eye research.
[5] D. Zacks,et al. Retinal cell death and current strategies in retinal neuroprotection , 2014, Current opinion in ophthalmology.
[6] D. Eliott,et al. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? , 2014, Progress in Retinal and Eye Research.
[7] N. Radke,et al. Comment on ‘Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy’ , 2014, Eye.
[8] Joan W. Miller,et al. Photoreceptor cell death and rescue in retinal detachment and degenerations , 2013, Progress in Retinal and Eye Research.
[9] C. Bunce,et al. Ozurdex® (a slow-release dexamethasone implant) in proliferative vitreoretinopathy: study protocol for a randomised controlled trial , 2013, Trials.
[10] A. Capone,et al. MICROPLASMIN (OCRIPLASMIN) IN PEDIATRIC VITREORETINAL SURGERY: Update and Review , 2013, Retina.
[11] A. Wright,et al. Long-term visual acuity and the duration of macular detachment: findings from a prospective population-based study , 2012, British Journal of Ophthalmology.
[12] Zhi Zheng,et al. Necrostatin-1 protects photoreceptors from cell death and improves functional outcome after experimental retinal detachment. , 2012, The American journal of pathology.
[13] Mark W. Johnson,et al. PARS PLANA VITRECTOMY WITHOUT ADJUVANT PROCEDURES FOR REPAIR OF PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT , 2012, Retina.
[14] F. Koerner,et al. Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.
[15] A. Wright,et al. Surgical outcome and risk stratification for primary retinal detachment repair: results from the Scottish Retinal Detachment study , 2012, British Journal of Ophthalmology.
[16] M. Gharbiya,et al. CORRELATION BETWEEN SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY FINDINGS AND VISUAL OUTCOME AFTER PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT REPAIR , 2012, Retina.
[17] Joan W. Miller,et al. Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment. , 2011, Investigative ophthalmology & visual science.
[18] Joan W. Miller,et al. Tauroursodeoxycholic Acid (TUDCA) Protects Photoreceptors from Cell Death after Experimental Retinal Detachment , 2011, PloS one.
[19] Joan W. Miller,et al. Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis , 2010, Proceedings of the National Academy of Sciences.
[20] Lloyd Paul Aiello,et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.
[21] H. Ahmadieh,et al. Effect of Oral Prednisolone on Visual Outcomes and Complications after Scleral Buckling , 2010, European journal of ophthalmology.
[22] E. A. Chapin,et al. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. , 2010, Investigative ophthalmology & visual science.
[23] D. Chen,et al. Minocycline inhibition of photoreceptor degeneration. , 2009, Archives of ophthalmology.
[24] E. A. Chapin,et al. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. , 2009, Investigative ophthalmology & visual science.
[25] A. Hafezi-Moghadam,et al. Role of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target , 2008, Proceedings of the National Academy of Sciences.
[26] H. Ahmadieh,et al. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. , 2008, Ophthalmology.
[27] D. Hu,et al. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. , 2008, American journal of ophthalmology.
[28] Ying Han,et al. Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. , 2008, Investigative ophthalmology & visual science.
[29] T. Sakamoto,et al. One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.
[30] Michael D. Ober,et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. , 2007, A M A Archives of Ophthalmology.
[31] G. Gettinby,et al. Prophylaxis of postoperative endophthalmitis following cataract surgery: Results of the ESCRS multicenter study and identification of risk factors , 2007, Journal of cataract and refractive surgery.
[32] C. Bunce,et al. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. , 2007, Ophthalmology.
[33] C. Bunce,et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. , 2004, Ophthalmology.
[34] Geoffrey P Lewis,et al. The efficacy of delayed oxygen therapy in the treatment of experimental retinal detachment. , 2004, American journal of ophthalmology.
[35] Arvydas Maminishkis,et al. The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat. , 2002, Investigative ophthalmology & visual science.
[36] C. Toth,et al. Effect of INS37217, a P2Y(2) receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits. , 2002, Investigative ophthalmology & visual science.
[37] Atul Kumar,et al. Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery , 2002, Clinical & experimental ophthalmology.
[38] P. Khaw,et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. , 2001, Ophthalmology.
[39] K Mervin,et al. Limiting the proliferation and reactivity of retinal Müller cells during experimental retinal detachment: the value of oxygen supplementation. , 1999, American journal of ophthalmology.
[40] K Mervin,et al. Limiting photoreceptor death and deconstruction during experimental retinal detachment: the value of oxygen supplementation. , 1999, American journal of ophthalmology.
[41] P. Wiedemann,et al. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. , 1998, American journal of ophthalmology.
[42] G. Lewis,et al. Alkylphosphocholines: a new approach to inhibit cell proliferation in proliferative vitreoretinopathy. , 2009, Developments in ophthalmology.